tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

IKT Stock Latest News

Inhibikase Therapeutics Advances PAH Treatment with New Leadership
Company AnnouncementsInhibikase Therapeutics Advances PAH Treatment with New Leadership
5d ago
IKT
Inhibikase Therapeutics Appoints New Chief Financial Officer
PremiumCompany Announcements
Inhibikase Therapeutics Appoints New Chief Financial Officer
6d ago
8K
IKT
Inhibikase Therapeutics announces appointment of McIntyre as CFO
PremiumThe Fly
Inhibikase Therapeutics announces appointment of McIntyre as CFO
6d ago
IKT
Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
26d ago
IKT
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals
PremiumCompany Announcements
Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals
2M ago
8K
IKT
Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO
PremiumThe FlyInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO
2M ago
IKT
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO
Premium
Company Announcements
Inhibikase Therapeutics Appoints Mark Iwicki as New CEO
2M ago
8K
IKT
Inhibikase Therapeutics appoints Mark Iwicki as CEO
Premium
The Fly
Inhibikase Therapeutics appoints Mark Iwicki as CEO
2M ago
IKT
Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
2M ago
IKT
Inhibikase Adjusts and Terminates Stock Offering Agreement
PremiumCompany Announcements
Inhibikase Adjusts and Terminates Stock Offering Agreement
5M ago
8K
IKT
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders
PremiumThe Fly
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders
5M ago
IKT
Inhibikase Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q3 2024 Financial Results
5M ago
IKT
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c)
PremiumThe FlyInhibikase Therapeutics reports Q3 EPS (65c), consensus (48c)
5M ago
IKT
Inhibikase Therapeutics, Inc. (IKT) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Inhibikase Therapeutics, Inc. (IKT) Q3 Earnings Cheat Sheet
5M ago
IKT
Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
Premium
The Fly
Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
5M ago
HD
SG
Inhibikase Therapeutics initiated with a Buy at Jefferies
PremiumThe Fly
Inhibikase Therapeutics initiated with a Buy at Jefferies
5M ago
IKT
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
PremiumCompany Announcements
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
6M ago
8K
IKT
Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro
PremiumThe Fly
Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro
6M ago
IKT
Inhibikase Therapeutics price target lowered to $5 from $15 at H.C. Wainwright
PremiumThe Fly
Inhibikase Therapeutics price target lowered to $5 from $15 at H.C. Wainwright
6M ago
IKT
Inhibikase Therapeutics Secures $110M for Drug Development
PremiumCompany AnnouncementsInhibikase Therapeutics Secures $110M for Drug Development
6M ago
8K
IKT
Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement
Premium
The Fly
Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement
6M ago
IKT
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
Premium
Company Announcements
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
6M ago
8K
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >